Oral delivery of proteins for biomedical use

Our technology allows the enzyme-mediated surface derivatization of the purified spheres with any molecule of choice, from small molecules (fluorophores, peptides, adjuvants…) to large substrates (proteins, affibodies, nanobodies…). Such covalent modification does not affect the properties and activity of the encapsulated protein.

Competitive Advantages

✅ Simple and scalable process: Single-step method, no special reagents or expensive equipment required.
✅ Total protection: Proven in vitro and in vivo. Protects against denaturation and degradation.
✅ Targeted delivery: Enzymatic surface modification without affecting the encapsulated protein.
✅ Cost reduction: Eliminates the need for cold storage and medical administration.
✅ Versatility: Applicable to multiple high-impact therapies.

Proof of Concept:  phenylketonuria

Materials Today Bio 33 (2025) 1019872.

Using this technology we have produced a nanosphere-encapsulated and chitosan-coated active form of Anabaena variabilis (AvPAL), used as an injectable therapeutic agent for treating phenylketonuria in clinical settings, that is extremely resistant to acid pH and degradation by proteases.

The biocompatible polymer increases their intestinal absorption and bioavailability of encapsulated proteins following oral administration, resisting the full gastrointestinal tract while fully available, showing its potential for the oral delivery of bioactive peptides.